ReviewNature reviews. Cardiology2026
Heart-on-a-chip and vasculature-on-a-chip platforms as models of cardiovascular disease.
Review in Nature reviews. Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Induced Pluripotent Stem Cell-Based Platforms for Cardiac-Related Pain Research: Molecular Mechanisms, Experimental Models, and Therapeutic Applications.International journal of molecular sciences · 2026Review
- Cardiac microphysiological systems in cardiovascular research: Construction paradigms, maturation trajectories, and translational frontiers.Bioengineering & translational medicine · 2026Review
- Immunoengineering in the field of tendon and bone regeneration: immunomodulatory biomaterials, delivery platforms, and preclinical models for chronic diseases.Frontiers in bioengineering and biotechnology · 2026Review
- Decoding Vascular Senescence: Cellular Insights and Therapeutic Strategies.International journal of biological sciences · 2026Review
- Humanized hiPSC Platforms for I/R Injury: Advancing Toward Precision Cardioprotection.Cardiovascular therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organ-on-a-chip platforms have revolutionized the modelling of cardiovascular pathophysiology, enabling researchers to elucidate underlying mechanisms and drug responses for a variety of inherited and acquired diseases. This emerging technology can overcome the limitations of traditional in vitro culture systems and animal models such as poor biological relevance and species-specific differences. Heart-on-a-chip and vasculature-on-a-chip models consist of 3D structures incorporating relevant cell populations (often derived from pluripotent stem cell sources) with precisely controlled electromechanical conditions and biochemical stimuli to form functional biomimetic microenvironments. These tunable platforms hold great promise in establishing patient-specific disease models and accelerating drug discovery and development, an important step in the direction of personalized cardiovascular medicine. In this Review, we highlight organ-on-a-chip models that have successfully mimicked cardiovascular disease phenotypes and contributed to the development of novel therapeutics, and summarize the technical and biological barriers to the widespread utilization of this technology.
Indexed as
Identifiers
41673471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.